September 2017 Scorecard

The September scorecard for the signals generated from Sonal can be downloaded here. The results are summarized in this table: Scorecard Total Repurchases M&A Guidance Contracts Clinical Trials Correct – Prev Close to Next Close 68% 59% 68% 93% 64% 68% Correct – Prev Close to Next Session Peak 92% 85% 90% 100% 100% 94% […]

Read more...

FLIR Systems Receives U.S. Military Contract

Sensor systems developer, FLIR Systems (FLIR), landed a $74.7 million contract with the U.S. military on October 2. They will provide TacFLIR surveillance cameras in support of the U.S. Army EO/IR-Force Protection (FP) program.   Sonal detected the event and sent an alert at 8:00 am. The next trade occurred during the pre-market trading hours […]

Read more...

Novo Nordisk Gets FDA Approval For Fast-Acting Insulin

On September 29, the FDA approved Novo-Nordisk’s (NVO) new drug to treat diabetes. Fiasp is fast-acting insulin that controls post-meal spikes in blood sugar. It works faster than existing drugs on the market and is already approved in both Canada and Europe.   Sonal caught the news and sent an alert at 11:03 am. The […]

Read more...

Zoegenix Climbs on Clinical Trial Results

On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome.   Sonal caught the news at 7:00 am and sent out a level 2 alert. The stock price immediately surged but then faded after the […]

Read more...

FDA Accepts Application for Investigational New Drug From Sangamo and Bioverativ

On October 2, Sangamo Biosciences (SGMO) and Bioverativ Inc. (BIVV) announced that the FDA accepted their application for an investigational new drug (IND). The drug, ST-400, is a gene-edited cell therapy candidate for people with transfusion-dependent-beta-thalassemia. There are about 100,000 patients being treated worldwide for this disease, which requires frequent blood transfusions.   Sonal sent […]

Read more...

Akebia Reports Successful Clinical Trial Results

On September 26, Akebia Therapeutics (AKBA) reported positive results from a phase 2 clinical trial of the drug Vadadustat. The study results came from Japanese patients with anemia associated with non-dialysis chronic kidney disease and confirmed prior findings.   Sonal detected the event and sent out an alert at 7:00 am. The next trade occurred […]

Read more...